Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India

(Novartis, 1 April 2013) "A decision issued today by the Indian Supreme Court regarding the Novartis breakthrough medicine Glivec® (imatinib mesylate) provides clarification on Indian patent law and discourages innovative drug discovery essential to advancing medical science for patients."